Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease

K. Tebbi, Cameron; B. London, Wendy; L. Friedman, Debra; Villaluna, Doojduen; A. de Alarcón, Pedro; S. Constine, Louis; P. Mendenhall, Nancy; Sposto, Richard; R. Chauvenet, Allen; L. Schwartz, Cindy

doi:10.1200/jco.2005.02.3879

Public

Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease

Published in Journal of Clinical Oncology • Feb 9, 2007

Authors:

Cameron K. Tebbi

Wendy B. London

Debra L. Friedman

Abstract

PURPOSE: Pediatric Oncology Group (POG) studies 9426 and 9425 evaluated dexrazoxane (DRZ) as a cardiopulmonary protectant during treatment for Hodgkin's disease (HD). We evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and second malignant neoplasms...

Subject

Medicine

Internal medicine

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!